Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap

Kayser, Cristiane; Alvarenga, M. C. V.; Neves, António; Lima, M. Gerbase‐De; Andrade, Luís Eduardo Coelho

doi:10.1080/03009740510026346

Cited by 16 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(11–14, 21, 25, 26) We examined associations with anti-PAD4 antibodies in RA and found that anti-PAD4 positivity was associated with disease duration and anti-CCP positivity. There was a non-significant trend toward lower prevalence of smoking among RA probands with anti-PAD4 antibodies compared to those without anti-PAD4 antibodies and no association with shared epitope alleles.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-degree Relatives in Indigenous North American Populations

Ferucci

Darrah²,

Smolik³

et al. 2013

J Rheumatol

View full text Add to dashboard Cite

Objective The objective of this study was to determine whether anti-peptidylarginine deiminase type 4 (PAD4) antibodies were present in first-degree relatives of rheumatoid arthritis (RA) patients in two indigenous North American populations with high prevalence of RA. Methods Participants were recruited from two indigenous populations in Canada and the United States, including RA patients (probands), their unaffected first-degree relatives, and healthy unrelated controls. Sera were tested for the presence of anti-PAD4 antibodies, anti-cyclic citrullinated peptide (CCP) antibodies, and rheumatoid factor (RF). HLA-DRB1 subtyping was performed and participants were classified according to number of shared epitope alleles present. Results Antibodies to PAD4 were detected in 24 of 82 (29.3%) probands; 2 of 147 (1.4%) relatives; and no controls (p <0.0001). Anti-CCP was present in 39/144 (27.1%) of the relatives, and there was no overlap between positivity for anti-CCP and PAD4 in the relatives. In RA patients, anti-PAD4 antibodies were associated with disease duration (p=0.0082) and anti-CCP antibodies (p=0.008), but not smoking or shared epitope alleles. Conclusion Despite a significant prevalence of anti-CCP in first-degree relatives, anti-PAD4 antibodies were almost exclusively found in established RA. The prevalence of anti-PAD4 antibodies in RA is similar to the prevalence described in other populations and these autoantibodies are associated with disease duration and anti-CCP in RA.

show abstract

Section: Discussionmentioning

confidence: 99%

“…(8–10) Several studies have described the presence of autoantibodies directed against peptidyl arginine deiminase type 4 (PAD4) in a subset of patients with RA. (11–14) In established RA, anti-PAD4 antibodies have been associated with anti-cyclic citrullinated peptide (CCP) antibodies and more severe disease. (11–13)…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-degree Relatives in Indigenous North American Populations

Ferucci

Darrah²,

Smolik³

et al. 2013

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Among these proteins, only one, PAD4, the enzyme that converts arginine into citrulline, was already known to be a target for RA autoantibodies [4-8]. Autoantibodies to PAD4 are more frequent in established than in early RA.…”

Section: Discussionmentioning

confidence: 99%

New autoantibodies in early rheumatoid arthritis

et al. 2013

View full text Add to dashboard Cite

IntroductionRheumatoid arthritis (RA) is a chronic inflammatory joint disease causing articular cartilage and bone destruction. Since irreversible joint destruction can be prevented by intervention at the early stages of disease, early diagnosis of RA is important. In this study, we identified new autoantibodies in the sera of patients with early (less than one year) RA.MethodsWe screened the sera of 20 RA patients with disease duration less than one year, 19 RA patients with disease duration more than five years and 23 controls on 8,268 human protein arrays. We confirmed the validity of protein array detection by ELISA assays. We then performed epitope mapping with overlapping 15-mers to analyze RA sera reactivity.ResultsWIBG (within BGCN homolog (Drosophila)), GABARAPL2 (GABA(A) receptor associated protein like 2) and ZNF706 (zinc finger protein 706) proteins are preferentially recognized by autoantibodies from early RA patients. Of interest, autoantibodies to WIBG are very specific for early RA. Indeed, 33% of early RA patients' sera recognize WIBG versus 5% of RA patients with disease duration more than 5 years and 2% of controls. We identified three linear peptides on WIBG GABARAPL2 and ZNF706 that are preferentially recognized by sera of early RA patients.ConclusionsWe identified new autoantibodies associated with RA with disease duration less than one year. These autoantibodies could be used as diagnosis markers in RA patients.

show abstract

“…about 22% of SSc patients [5]. However, in some cases there are no joint symptoms of SSc, but there are manifestations of AS [6][7][8][9][10]. Although the two diseases manifested independently in our patient, there seem to be common features among patients with both diseases.…”

Section: Figurementioning

confidence: 71%

Systemic Sclerosis and Pleural Effusion in a Patient with Ankylosing Spondylitis

Koo¹,

Song²,

Lee³

et al. 2018

Korean J Med

View full text Add to dashboard Cite

Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap

Cited by 16 publications

References 9 publications

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-degree Relatives in Indigenous North American Populations

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-degree Relatives in Indigenous North American Populations

New autoantibodies in early rheumatoid arthritis

Systemic Sclerosis and Pleural Effusion in a Patient with Ankylosing Spondylitis

Contact Info

Product

Resources

About